Takeda
Novartis accuses ex-employee of stealing confidential files for Takeda
Novartis is pursuing legal action against a former employee from its Egyptian affiliate, who is alleged to have taken thousands ...
Takeda writes off $770M after failures of Alofisel and Exkivity
Takeda, the Japanese pharmaceutical company, is grappling with significant impairment charges totaling 115.8 billion Japanese yen ($770 million) in its ...
Takeda’s Alofisel fails to meet primary endpoint in phase 3 trial for Crohn’s disease complication
Takeda, following its decision to remove an early-stage Crohn’s disease candidate from its pipeline earlier this year, is now contending ...
Takeda withdraw Global Lung Cancer Medication, Exkivity, Following Confirmatory Trial Failure
Following a disappointing outcome in a confirmatory trial earlier this year, Takeda has decided to discontinue its targeted non-small cell ...
Takeda licenses AcuraStem’s antisense drug for ALS targeting PIKFYVE
As scientific research continues to underscore the potential of targeting the PIKFYVE enzyme in the quest to combat amyotrophic lateral ...
Morphic’s Shares Tumble as Updated Phase 2 Data Casts Shadows on Takeda’s Entyvio Rival
Morphic Therapeutic has encountered a setback, as more comprehensive data from its much-anticipated EMERALD-1 trial unveiled uncertainties, causing its stock ...
Takeda reaches settlement with drug wholesalers over alleged pay-for-delay scheme for Colcrys
Takeda, the Japanese pharmaceutical giant, has reached a settlement in an antitrust case that has been looming over the company. ...
Takeda Ordered To Pay AbbVie $480m For Failing To Supply Lupron
AbbVie stands to potentially receive significant damages, possibly amounting to hundreds of millions of dollars, due to a contractual manufacturing ...
Nimbus Raises $210M To Advance Small Molecule Pipeline, Honors Late Founder
Nimbus Therapeutics, with its experienced leadership, well-established R&D platform, and substantial financing, appears well-positioned for success in the public markets. ...
Takeda’s Vyvanse faces generic competition after 16 years of ADHD dominance
Vyvanse, a blockbuster drug for attention-deficit/hyperactivity disorder (ADHD) and binge-eating disorder, has been the top choice for many patients and ...
Horizon Surpasses Roche in Rare Disease Reputation, While Pfizer’s Standing Declines
Horizon Therapeutics continues to collect accolades as it progresses toward its acquisition, with rare disease organizations now recognizing its excellence. ...
Takeda pays $42M to resolve Texas Medicaid fraud charges
In the wake of a whistleblower lawsuit alleging Takeda and its affiliated companies of engaging in Medicaid fraud through illicit ...
Lonsurf gets a boost from FDA for colorectal cancer, challenging rivals Takeda and Hutchmed
Source – Taiho Oncology Eight years after initially gaining FDA approval for the treatment of heavily pretreated colorectal cancer, Taiho ...
As Vyvanse generics loom, Takeda exaggerates the progress of the dengue vaccine launch
As generics of the popular ADHD medication Vyvanse loom on the horizon, Takeda is looking to rely on newer launches ...
Takeda withdraws its FDA application for a dengue vaccine due to data disagreements with the authority
Source: Takeda Takeda announced on 11 July that it is withdrawing its application for the dengue vaccine candidate, TAK-003, from ...
TAK-755 Prophylaxis Shows Promise in Managing cTTP: ISTH 2023 Congress Highlights
Source – Takeda On June 25, 2023, Takeda has shared promising interim findings from a global Phase III clinical trial ...
Takeda Unveils Complete Phase III Trial Results for HYQVIA as Maintenance Therapy in CIDP at PNS Annual Meeting
Source: Takeda Takeda on June 20, 2023, released the complete findings from the pivotal Phase III ADVANCE-CIDP 1 clinical trial, ...
Vyvanse Joins Adderall in Short Supply as Takeda’s Rival Faces Shortages
Source – Fierce Pharma A competitor medication from Takeda is currently in low supply after a lengthy scarcity of the ...
